Boryung Biopharma said that Monday that it plans to launch the “Mom Scanning Plus,” a non-invasive prenatal test, along with CancerRop, a local firm that exposes genetic disorders using molecular diagnosis.

The test utilizes the database of G-Scanning plus, a test that can diagnose neonatal developmental diseases through genetic analysis and can detect more than 100 different micro-gene deletions and overlap diseases.

As the test covers a wider area compared to conventional non-invasive prenatal screening tests that can only screen for 10 diseases, the company expects that the test can lower the financial burden of patients.

Noninvasive prenatal screening is a technique which extracts fetal DNA in the blood of pregnant women to identify chromosome aberrations such as Down, Edward, and Patau syndrome. Unlike conventional amniocentesis which inserted long needles, it is easy and safe as it only requires the blood of the pregnant women.